

## 10-7599: Monoclonal antibody to Human PD-L1 (Clone: ABM5F25)

|                                |  |
|--------------------------------|--|
| <b>Clonality :</b>             | Monoclonal   |
| <b>Clone Name :</b>            | ABM5F25  |
| <b>Application :</b>           | IHC,FACS,WB  |
| <b>Reactivity :</b>            | Human  |
| <b>Gene :</b>                  | CD274  |
| <b>Gene ID :</b>               | 29126  |
| <b>Uniprot ID :</b>            | Q9NZQ7   |
| <b>Format :</b>                | Purified   |
| <b>Alternative Name :</b>      | CD274,B7H1,PDCD1L1,PDCD1LG1,PDL1   |
| <b>Isotype :</b>               | Mouse IgG2b Kappa  |
| <b>Immunogen Information :</b> | A partial length recombinant protein of PD-L1 (amino acid 13-224) was used as the immunogen for this antibody. |

### Description

PD-L1 (CD274/B7-H1) is a critical membrane-bound costimulatory molecule belonging to the B7 superfamily that inhibits immune responses through its receptor, PD-1. PD-L1 plays a key role in the pathogenesis of inflammatory diseases (programmed death 1). It is widely expressed in the mononuclear phagocyte system (MPS), may co-stimulate T cells, and regulates inflammatory responses. PD-L1 exerts inflammation regulatory functions via a negative co-stimulatory effect on T cell functions to inhibit cytokine secretion, facilitates apoptosis of activated T cells, and induces T cell anergy. Aberrant expression and dysregulation of CD274 have been reported during bacterial infection, inflammation, and in numerous autoimmune diseases.

### Product Info

|                            |   |
|----------------------------|---|
| <b>Amount :</b>            | 25 µg / 100 µg  |
| <b>Purification :</b>      | Protein G Chromatography  |
| <b>Content :</b>           | 25 µg in 50 µl/100 µg in 200 µl PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic.                |
| <b>Storage condition :</b> | Store the antibody at 4°C; stable for 6 months. For long-term storage; store at -20°C. Avoid repeated freeze and thaw cycles. |

### Application Note

FACS analysis: 0.5-1 µg/10<sup>6</sup> cells; Western blot analysis: 2-4 µg/ml; Immunohistochemical analysis: 5-10 µg/ml




Fig:1- Cell Surface flow analysis of PD-L1 in 3 day-PHA treated human PBMC cells using  $1 \mu\text{g}/10^6$  cells of PD-L1 antibody (Clone: ABM5F25). Green represents isotype control; red represents anti-PD-L1 antibody. Goat anti-mouse PE conjugate was used as secondary antibody.




Fig-2: Cell surface flow analysis of PD-L1 in CHO-PD-L1 transfected cell line using  $0.5 \mu\text{g}/10^6$  cells of PD-L1 antibody (Clone: ABM5F25). Green represents isotype control; red represents anti-PD-L1 antibody. Goat anti-mouse PE conjugate was used as secondary antibody.




Fig-3: Western blot analysis of PDL1. Anti-PD-L1 antibody (Clone: ABM5F25) was tested at  $0.5 \mu\text{g}/\text{ml}$  on Recombinant lysate.




Fig-4: Western blot analysis of PDL1. Anti-PD-L1 antibody (Clone: ABM5F25) was tested at  $2 \mu\text{g}/\text{ml}$  on (1) Daudi and (2) HepG2 lysates.




Fig-5: Immunohistochemical analysis of PD-L1 in Hodgkin's Lymphoma tissue using PD-L1 antibody (Clone: ABM5F25) at 5  $\mu$ g/ml.




Fig-6: Western blot analysis of PDL1. Anti-PD-L1 antibody (Clone: ABM5F25) was tested at 0.5  $\mu$ g/ml on (1) U87 and (2) THP1 lysates.